SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Mutations in ASXL1 (ASXL1-MT) are common in myelodysplastic syndrome (MDS) and linked to poor outcomes.
• The exact molecular mechanisms driving ASXL1-MT in MDS remain unclear.
• ASXL1 loss or C-terminal truncations impair myeloid differentiation and cause MDS-like conditions in mice.

Purpose of the Study:

• Investigate the role of SETBP1 mutations (SETBP1-MT) in ASXL1-mutated MDS.
• Elucidate the molecular pathways affected by SETBP1-MT in MDS pathogenesis.
• Identify potential therapeutic targets for high-risk MDS.

Main Methods:

• Analyzed SETBP1 mutation frequency in ASXL1-mutated MDS patients.
• Investigated the impact of SETBP1-MT on SETBP1 protein stability and expression.
• Assessed the effects of SETBP1-MT on protein phosphatase 2A activity, Akt signaling, and Hoxa gene expression.
• Evaluated the collaborative effects of ASXL1-MT and SETBP1-MT in myeloid differentiation, apoptosis, colony formation, and leukemogenesis in vivo.
• Compared molecular signatures between ASXL1-MT and combined ASXL1-MT/SETBP1-MT models.

Main Results:

• SETBP1-MT are enriched in ASXL1-mutated MDS patients, correlating with higher risks of leukemic transformation and shorter survival.
• SETBP1-MT prevent SETBP1 ubiquitination and degradation, leading to increased SETBP1 protein levels.
• Elevated SETBP1 inhibits protein phosphatase 2A, activates Akt, and upregulates posterior Hoxa genes.
• SETBP1-MT exacerbate ASXL1-MT-induced differentiation block, reduce apoptosis, and increase myeloid colony output.
• Combined ASXL1-MT and SETBP1-MT induce acute myeloid leukemia in vivo, activating a stem cell signature and repressing TGF-β signaling.

Conclusions:

• SETBP1-MT are critical drivers of leukemic transformation in ASXL1-mutated MDS.
• SETBP1 stabilization and subsequent pathway dysregulation are key mechanisms in ASXL1-mutated MDS progression.
• Targeting the identified deregulated pathways may offer therapeutic strategies for high-risk MDS.